Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Haroldsen, Anne
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	NA	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25
MAbPACs, NCT05013723: Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome	Completed	N/A	260	US	Surveys	Intermountain Health Care, Inc., Regeneron Pharmaceuticals	Post-acute COVID-19 (PACS), or "long COVID" Syndrome	12/22	12/22
Hossain, Zakir
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	NA	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25
McComb, Holly
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	NA	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis	Active, not recruiting	1/2	42	US	CNP-104, Placebo	COUR Pharmaceutical Development Company, Inc.	Primary Biliary Cholangitis	01/26	01/26
Unsworth, Anika
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27